ArticleCancers2023
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Juan Pablo Muñoz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled ittrialcites it